Loading...
•
Dec 31, 2020
Moderna Q4 2020 Earnings Report
Moderna's financial results for Q4 2020 were reported, highlighting increased revenue driven by grant revenue and product sales, along with updates on vaccine manufacturing and pipeline progress.
Key Takeaways
Moderna reported a significant increase in revenue for Q4 2020, driven by grant revenue and product sales of its COVID-19 vaccine. The company is expanding its manufacturing capabilities and advancing its mRNA development programs.
Moderna raised the lower end of its 2021 global manufacturing plan from 600 million to 700 million doses.
The company is making capital investments to increase manufacturing capacity up to 1.4 billion doses in 2022.
Moderna established 8 commercial subsidiaries in 2020 and plans to expand to Japan, South Korea, and Australia in 2021.
The Phase 2/3 study of mRNA-1273 in adolescents has completed enrollment of 3,000 participants.
Moderna
Moderna
Forward Guidance
Moderna anticipates approximately $18.4 billion in product sales from already signed APAs for scheduled delivery in 2021. The cost of sales is expected to be approximately 20% of product sales for fiscal year 2021.
Positive Outlook
- Signed APAs reflect $18.4 billion in anticipated product sales for 2021.
- Additional discussions are ongoing with governments for 2021 and 2022 deliveries.
- Replied to UNICEF tender to supply COVAX in 2021 and 2022.
- Effective tax rate expected in the mid-teen percentage level.
- Planned capital investments of $350-400 million for 2021.
Challenges Ahead
- R&D and SG&A expenses expected to increase in Q1 2021.
- The fourth quarter 2020 reported expense was $0.8 billion.
- Adjusted Q4 expense, totaling $0.5 billion, excludes $0.3 billion of reported expenses
- Expenses are now capitalized and expensed through cost of sales.
- Change from a research and development to a commercial organization.